单国洪先生于2017年9月18日起出任武田中国总裁，常驻上海，全面负责武田中国（包括香港、澳门地区）的整体战略及业务增长，同时也是武田成长与新兴市场管理层委员。在他的领导下，武田中国成功实现了战略转型，近年来业务高速发展，中国市场已成为武田全球最重要的战略市场之一。

单国洪先生拥有逾二十年以上行业管理经验，对中国的医疗及制药行业有着独到的洞察和深刻的认知。在加入武田之前，他曾出任辉瑞创新集团中国区总经理、阿斯利康中国区副总裁等跨国药企高级管理职位；同时还曾担任辉瑞全球肿瘤委员会，阿斯利康全球呼吸领域品牌委员会成员等职务。凭借其丰富的国际化管理经验以及深刻的行业洞察力，他曾成功地领导了肿瘤、免疫、罕见病及疫苗等多个疾病领域的创新产品在中国大陆、香港及澳门地区的获批与上市，使这些创新药品更早惠及中国患者。

作为一名医疗行业资深专业人士，单国洪先生活跃于各项社会事务，并担任多个社会职务。他是中国癌症基金会和中国医药生物技术协会的常务理事，中国外商投资企业协会药品研制和开发行业委员会（RDPAC）执行委员会委员，也是复旦大学管理学院的校友导师，并拥有美国华盛顿大学和复旦大学高级工商管理硕士（EMBA）学位。

 Sean Shan has been appointed as President of Takeda China since 18 September 2017, taking full responsibilities for Takeda’s overall strategy and business development in China, including Hong Kong and Macao. In addition to his role as China head, he also sits on the Leadership Committee of Growth & Emerging Markets of Takeda, representing China market. Under his leadership Takeda China has accelerated its strategic transformation with great success recently. The businesses keep a fast pace with strong growth across broad therapeutic areas. China now is seen one of the most important strategic markets at Takeda worldwide.

 Bringing his over 20 years’ experiences in pharmaceutical industry in China, Sean is a seasoned executive with versatile functional expertise in marketing and sales, business development. Before joining Takeda, he took several roles as senior executive in the leading MNCs, such as General Manager of Innovation Healthcare of Pfizer China, Vice President of Astra Zeneca China etc. Apart from his country leadership role, he also held global key positions as the member of Global Oncology Council of Pfizer, Global Respiratory Brand Council of Astra Zeneca. Combining his international leadership experience and in-depth functional expertise in pharmaceutical industry, he has been leading several new drugs approval and launch across mainland China, Hong Kong and Macao, with specific to oncology, immunology, rare disease and vaccine. More Chinese patients are benefitting now from these innovative medicines.

 As a senior healthcare professional Sean has been proactively taking social responsibilities and roles. He is now a standing member of the board of China Cancer Foundation and China Medical and Biotechnological Association, executive committee member of RDPAC, and alumina tutor of Management School of Fudan University. He possesses EMBA from University of Washington and Fudan University. Sean and his family are based in Shanghai.